101 results about "Acyltransferase" patented technology

Compounds and compositions comprising compounds that modulate histone acyltransferase (HAT). Methods of treating neurodegenerative disorders, conditions associated with amyloid-beta peptide deposit accumulation, Tau protein levels, and / or alpha-synuclein accumulation, and cancer by administering to a subject a compound that modulates HAT.

The invention discloses a recombinant bacterium capable of increasing the yield of alpha-bisabolol as well as a preparation method and application of the recombinant bacterium, and belongs to the technical field of microorganisms. The invention aims to improve the yield of alpha-bisabolol and enhance the tolerance of a host to an organic solvent. The invention provides a recombinant bacterium for improving the yield of alpha-bisabolol. Escherichia coli is used as a starting strain; the method comprises the following steps of: overexpressing an acetyl CoA acyltransferase / HMG-CoA reductase mvaE gene, an HMG-CoA synthetase mvaS gene, a 2-methyl citrate dehydratase prpD gene, a mevalonate kinase ERG12 gene, a mevalonate 5-phosphate kinase ERG8 gene, a mevalonate 5-diphosphate decarboxylase ERG19 gene and an isopentenyl diphosphate isomerase idi gene, so as to obtain a recombinant vector; the gene is obtained from an alpha-bisabolol synthase gene of artichoke, a farnesyl diphosphate synthase ispA gene and an alpha-bisabolol synthase CcBOS gene of artichoke. The industrial process of synthesizing alpha-bisabolol by a biological method is promoted.

The application provides a recombinant Yarrowia lipolytica capable of producing palmitoleic acid at a high yield, a construction method and application thereof, and belongs to the technical field of bioengineering. Yarrowia lipolytica The recombinant Yarrowia lipolytica is obtained by knocking out peroxisome biogenesis factor 10 and triacylglycerol lipase 4 in the genome of Yarrowia lipolytica and inserting an acetyl-CoA carboxylase, a Δ9 desaturase, an acetyl-CoA diacylglycerol acyltransferase, a glycerol-3-phosphate acyltransferase, a lysophosphatidylcholine acyltransferase and a phosphatidylcholine:diacylglycerol acyltransferase gene expression cassette. Experiment proves that the recombinant Yarrowia lipolytica can efficiently ferment and produce palmitoleic acid, and realizes efficient synthesis of the natural product palmitoleic acid from plants in Yarrowia lipolytica.

The present application relates to a kind of whole cell catalytic synthesis N-acetyl-trans-4-hydroxyproline method, belong to biological catalysis technical field.The present application is constructed by mutating acyltransferase and heterologous expression gene engineering bacteria, successfully realized using whole cell catalytic synthesis N-acetyl-trans-4-hydroxyproline, avoids the problem of enzyme instability, reduces the separation cost of enzyme and product.On this basis, the present application improves the yield of N-acetyl-trans-4-hydroxyproline by optimizing catalytic time, cell addition amount, the type and addition amount of additive, and the yield reaches 239mg / L.The present application is a kind of N-acetyl-trans-4-hydroxyproline preparation method with lower cost, lower equipment demand, more suitable for industrial production.

The invention relates to the field of genetic engineering and fermentation engineering, and discloses a genetically engineered bacterium for producing melatonin and application of the genetically engineered bacterium in fermentation production of melatonin. According to the invention, genes of mtrA, PTPS, SPR, PCD and DHPR of related enzymes synthesized by coding 2-amino-6-(1, 2-dihydroxypropyl)-5, 6, 7, 8-tetrahydro-4 (1H)-pterin diketone and genes of L-2-amino-3 (beta-indole) propionic acid monooxygenase, oxymethyltransferase, N-acetyltransferase and decarboxylase are co-expressed on the genetically engineered bacterium, so that the gene engineering bacterium is obtained. The strain can be used for fermentation production of melatonin, and experiments show that the yield of the strain can reach 6480 mg / L.

The present invention relates to the use of carnitine palmitoyltransferase 1 inhibitors in the treatment of heart failure with preserved ejection fraction. The use in particular is the use of the carnitine palmitoyltransferase (CPT1) inhibitor Etomoxir for the prevention and / or treatment of heart failure with preserved ejection fraction by oral administration.

The invention discloses yarrowia lipolytica engineering bacteria for producing esterified astaxanthin as well as a construction method and application of the yarrowia lipolytica engineering bacteria. According to the invention, acyltransferase ScDGAT2-1 from fission vibrio is integrated in a genome of a yarrowia lipolytica engineering strain DN20, diacylglycerol acyltransferase DGA1 and phosphatidic acid phosphatase PAH1 are knocked out, and the corn oil lipoprotein Oleosin and the acyltransferase ScDGAT2-1 from fission vibrio are subjected to fusion expression, so that the yarrowia lipolytica engineering strain DN20 is obtained. According to the present invention, the Yarrowia lipolytica engineering bacterium capable of producing esterified astaxanthin at a high yield is constructed by using SBT06-005 as a raw material and integrating beta-carotene hydroxylase CrtZ, endogenous truncated 3-hydroxy3-methylglutaryl coenzyme A reductase tHMG1, phytoene synthase CarRP and beta-isopropyl malate dehydrogenase LEU2, and the SBT06-005 can produce 166.6 mg / L esterified astaxanthin and 1097.0 mg / L total astaxanthin in a 5L fermentation tank.

The application discloses an engineering bacterium for producing N-acetyl-trans-4-hydroxyproline and application thereof and belongs to the technical field of biotechnology.The application realizes fermentation synthesis of N-acetyl-trans-4-hydroxyproline by taking proline as a substrate through mutation of acyltransferase and introduction of exogenous proline-4-hydroxylase.The application has the advantages of low production cost, short fermentation period and high strain stability and has high economic benefits.The recombinant strain constructed by the application can convert 0.5M of proline into 19.64mg / L of N-acetyl-trans-4-hydroxyproline.

The present application belongs to the technical field of quorum quenching enzyme preparation, and particularly relates to a multi-target quorum quenching enzyme preparation and a preparation method and application thereof, such as being mainly used for inhibiting the virulence factors of Pseudomonas aeruginosa, and including acyl homoserine lactone acyltransferase AiiO protein and 3-hydroxy-4-oxoquinolone 2,4-dioxygenase AqdC protein, and the mass ratio of the two is 20:(1-25); such as being mainly used for inhibiting the virulence factors and the synthesis of biological membranes of Pseudomonas aeruginosa, and further including deferiprone, and the mass ratio of AiiO, AqdC and deferiprone is 20:(1-25):(0.695-2.78), the present application can target the Las, Rhl and PQS of Pseudomonas aeruginosa, the yield and stability of the prepared AqdC protein are both high, the two types of enzymes are used in combination after the regulation amount, and the virulence factors regulated by different quorum sensing pathways in Pseudomonas aeruginosa are effectively inhibited; the regulation amount of deferiprone is used in combination with the two types of quorum quenching enzymes, and the virulence and biological membranes of Pseudomonas aeruginosa can be effectively inhibited in a comprehensive manner.

The invention relates to the technical field of plant growth regulation, in particular to application of berberine based on ACAA targets in resisting plant viruses and promoting plant growth. The invention reveals that berberine plays a role by specifically targeting acetyl coenzyme A acyltransferase and up-regulating the expression of the acetyl coenzyme A acyltransferase for the first time. The clear compound-target-pathway mechanism overcomes the defect that the existing plant source product mechanism is unknown. As the target spot is clear, the application dosage can be accurately controlled, so that the stability and predictability of field antiviral and growth promoting effects are ensured, and a foundation is laid for large-scale agricultural application. An ACAA target is activated by berberine, and an antiviral defense mechanism and an energy metabolism growth pathway of a plant can be synchronously started, so that the plant growth is effectively promoted while virus diseases are prevented and treated. The disease resistance-growth negative correlation problem existing in agricultural production for a long time is solved, and the dual requirements of modern agriculture for precise prevention and control and yield increase and quality improvement are met.

The invention belongs to the technical field of agricultural biology, and relates to application of glycerol acyltransferase with an amino acid sequence as shown in SEQ ID NO: 1 to improvement of salt tolerance of plants, and the glycerol acyltransferase is of great significance to creation of salt-tolerant plant germplasm resources and cultivation of salt-tolerant rice varieties.

The invention provides an engineering bacterium for producing spermidine and a preparation method of the engineering bacterium, and relates to the field of genetic engineering. According to the invention, arginine decarboxylase, aspartate kinase, aspartate-semialdehyde dehydrogenase, spermidine efflux protein (MdtI / MdtJ), carboxylaminopropyl agmatine dehydrogenase (CAPADH), carboxylaminopropyl agmatine decarboxylase (CAPADC) and aminopropyl agmatine urea hydrolase (APAUH) are subjected to overexpression in escherichia coli by using a gene engineering technology, and then the escherichia coli is subjected to enzyme deactivation, so that the escherichia coli is obtained. The genetically engineered bacterium capable of producing the spermidine can be obtained by simultaneously knocking out a spermidine transport system (PotBCAD), a spermidine-N-acetyltransferase (spermidine-N-acetyltransferase) and a homoserine dehydrogenase (homoserine dehydrogenase), so that the genetically engineered bacterium capable of producing the spermidine can be obtained. The engineering bacterium greatly reduces the production cost of spermidine, has a wide application prospect, and lays a foundation for green production of spermidine.

Disclosed are compounds of Formula I as well as pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The invention provides a bis-substituted phenyl acrylamide / ester compound as well as a preparation method and application thereof. The structural formula of the compound is shown as a formula (I) or a formula (II). The compound provided by the invention can be used as a covalent inhibitor of DHHC family proteins, and inhibits proliferation, migration and invasion of tumor cells and plays an anti-tumor role by inhibiting the activity of DHHC palmitoyltransferase and blocking the palmitoylation modification process of substrate proteins. Experimental results show that the bis-substituted phenylacrylamide / ester compound has remarkable anti-proliferative activity on various tumor cells, the inhibition effect of the compound is superior to that of a positive control drug 2-BP, and the bis-substituted phenylacrylamide / ester compound has the potential of being further developed into a new generation of efficient and low-toxicity anti-tumor drugs.

The invention discloses application of a membrane-bound O-acyltransferase structural domain 7 (Mboat7) in preparation of a medicine for treating myocardial infarction, and belongs to the technical field of biology. A research result shows that in a mouse myocardial infarction model, compared with a control group mouse, the death rate of a myocardial cell specific Mboat7 gene overexpressed mouse is reduced, the infarction area is remarkably reduced, and the cardiac function is remarkably improved; the overexpressed Mboat7 gene can relieve mitochondrial damage of myocardial cells under the hypoxia condition and improve the mitochondrial oxidative phosphorylation function. Particularly, overexpression of the Mboat7 gene can improve damage of mitochondria in myocardial tissues of mice suffering from myocardial infarction. The results show that Mboat7 gene overexpression can relieve myocardial damage after myocardial infarction so as to delay the progress of heart failure, and Mboat7 or an expression promoter thereof can be used for preparing the medicine for preventing, relieving and / or treating myocardial infarction.

The invention discloses ester-synthesized clostridium aerovorans as well as a construction method and application thereof, and belongs to the technical field of genetically engineered bacterium, genetically engineered clostridium aerovorans capable of synthesizing ester is constructed, a clostridium Yangtinctorii engineering strain synthesized by butanol is taken as a host, and alcohol acyltransferase ATF1 gene from saccharomyces cerevisiae is over-expressed, so that the ester-synthesized clostridium aerovorans is obtained. The clostridium Yangtsangensis genetic engineering strain capable of producing various esters is obtained; 1.4 g / L of butyl acetate can be obtained from the genetic engineering strain in serum bottle fermentation; the fermentation yield can be further increased in a 3L fermentation tank, 12.5 g / L of butyl acetate is obtained, and meanwhile, a small amount of ester compounds such as ethyl acetate, ethyl butyrate and butyl butyrate are obtained; the genetic engineering clostridium aerovorans disclosed by the invention is suitable for fermenting green gases such as synthesis gas serving as raw materials to synthesize green butyl acetate.

Methods and compositions for treating cancer e.g., liver cancer in a subject in need thereof are provided. Compositions including an effective amount of an 1-Acylglycerol-3-Phosphate O-Acyltransferase 4 (AGPAT4) inhibitor alone, or in combination with a kinase inhibitor and methods of use thereof for treating cancer are disclosed. The composition includes one or more small molecule inhibitors, inhibitory nucleic acids, or inhibitor proteins in a pharmaceutically acceptable carrier. Administration of the AGPAT4 inhibitor, alone or in combination with a kinase inhibitor is effective to reduce cancer cell proliferation or viability in a subject with cancer. Methods of selecting and treating subjects with cancers, particularly liver cancer are also provided.

The present invention relates to tomato plants having improved insect resistance, more specifically whitefly or mite resistance, comprising the ASAT3 gene encoding an acetyl-CoA-dependent acyltransferase enzyme and the AP2e gene encoding the APETALA2 ethylene-responsive transcription factor. The present invention further relates to methods for preparing tomato plants with improved insect resistance and to the use of the ASAT3 gene in combination with the AP2e gene to provide insect-resistant tomato plants.

The present application relates to the technical field of genetic engineering, and discloses a recombinant Escherichia coli for high-yield O-acetyl-L-homoserine and application thereof. The recombinant Escherichia coli for high-yield O-acetyl-L-homoserine is obtained by the following combination of modification strategies: in Escherichia coli W3110, a gene encoding homoserine O-acetyltransferase is integrated into a gene site encoding L-arginine ABC transporter ATP binding subunit, then a gene encoding phosphoacetyltransferase is knocked out, then a gene encoding transcriptional anti-terminator and mRNA stability regulator is knocked out, then a gene encoding ATP-NAD kinase is integrated into a gene site encoding NADPH-dependent aldehyde reductase, and finally a gene promoter of acetyl-CoA synthetase is replaced by a Ptrc promoter to obtain the recombinant Escherichia coli. The recombinant Escherichia coli is used for fermentation to produce O-acetyl-L-homoserine, and has the advantage of high yield. metx artp patz cspc ppnk yahk acs ​​​​​​​

The invention relates to the technical field of biological medicine, and discloses a binding peptide targeting a C-terminal structural domain of human AARS1 protein and application, the binding peptide comprises an amino acid sequence represented by a general formula (I) and a Val-Ala-Xaa-Xaa-Arg-His core motif, and can specifically bind to the C-terminal structural domain of the human AARS1 protein. The binding peptide and the derivative thereof block an AARS1 mediated protein lactic acid modification signal channel by inhibiting the activity of AARS1 lactoacyltransferase or inducing protein degradation through a ubiquitin-proteasome pathway. The binding peptide provided by the invention avoids an N-terminal catalytic activity center of AARS1, does not influence the protein synthesis function of normal cells while exerting antitumor activity, has relatively high affinity and safety, and can be used for preparing drugs for treating AARS1 mediated diseases such as pancreatic cancer or a diagnostic reagent for detecting AARS1.

The invention provides a transferase and a green enzymatic carnosine production method. The high-activity mutants of DmpA-2 and DmpA-6 are obtained by performing single-point or double-point mutation on the 86th site (E86V) and the 259th site (D259A) of wild type DmpA enzyme, so that the catalytic efficiency of the beta-amino acid ester acyltransferase is remarkably improved. According to the method, beta-alanine and L-histidine serve as substrates, recombinant bacteria are used for expressing mutant enzyme, carnosine is catalytically synthesized under the mild condition, the product concentration reaches 5.36 g / L and is 3.53 times that of a wild type, and the method has the advantages of being green in reaction condition, high in product purity and the like and is suitable for industrial production.

This invention relates to the construction and staining application of recombinant Escherichia coli for synthesizing indoleacetic acid ester. The recombinant Escherichia coli for synthesizing indoleacetic acid ester is obtained by using recombinant Escherichia coli MG1655ΔpheAΔtrpRΔtyrAΔyddGΔarsB::tac70-MaFMOΔldhA::tac70-MaFMOΔyghWX::tac70-tnaAΔpoxB::tac70-cav1 as the initial strain. Then, the endogenous acetylesterase is knocked out, and the endogenous tryptophan hydrolase gene tnaA and the flavin monooxygenase gene maFMO are overexpressed, while simultaneously overexpressing the acetyltransferase gene. The indoleacetic acid ester yield of this invention is as high as 195.3 mg / L. Using indoleacetic acid ester for staining eliminates the need for reducing agents and enzyme solutions, significantly reducing staining costs.

The application relates to the field of genetic engineering, discloses an acyltransferase CsHCT, the amino acid sequence of the acyltransferase CsHCT is shown as SEQ ID No: 1; further comprises a coding gene of the acyltransferase CsHCT; and application of the acyltransferase CsHCT and the coding gene thereof to in-vitro synthesis of kaempferol-3-O-(6'-coumaroyl)-glucoside. The application realizes in-vitro enzyme catalytic synthesis of kaempferol-3-O-(6'-coumaroyl)-glucoside, and simultaneously discloses a gene editing method, so that an enzyme capable of catalyzing synthesis of kaempferol-3-O-(6'-coumaroyl)-glucoside is obtained, and the enzyme exhibits certain application prospect in the field of biosynthesis of acylated kaempferol-3-O-glucoside.

The invention discloses a compound shown as a formula (I) or pharmaceutically acceptable salt, solvate, hydrate, stereoisomer or isotope isomer of the compound. A ring A and a ring B jointly form a fused ring. Ring A and ring B are independently selected from 5-10-membered aromatic rings and saturated or unsaturated aliphatic rings; the aromatic ring and the saturated or unsaturated aliphatic ring contain 0-3 O, N, S or carbonyl groups; the ring A and the ring B are optionally substituted by 0-3 Q1; q1 is defined in the specification; l is-CONH <->,-SO2NH <->,-NHCO <-> or NHSO2 <->; r1 and R2 are defined in the specification. A compound shown as a formula (I) or a pharmaceutically acceptable salt, a solvate, a hydrate, a stereoisomer or an isotope isomer thereof has excellent inhibitory activity on hemolytic cardiophosphatidyltransferase (ALCAT1), and can be used for preparing drugs for preventing or treating diseases related to the activity of the hemolytic cardiophosphatidyltransferase.

Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The application discloses a tylosin polyketide synthase acyltransferase mutant and application thereof, relates to the field of bioengineering, and comprises a first mutant, a second mutant or a third mutant; the amino acid sequences are shown in SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4 respectively. The application discloses a coding gene of the mutant, a recombination carrier and a recombination bacteria and application thereof in catalyzing malonyl-CoA hydrolysis. The application discloses a soluble expression method of tylosin polyketide synthase acyltransferase domain TylAT5 protein, which comprises culturing bacterial bodies, eluting target proteins and further purifying the target proteins by using fast protein liquid chromatography. The application provides a recombination escherichia coli which can efficiently express acyltransferase mutants, and the efficiency of catalyzing malonyl-CoA of the recombination escherichia coli is 2.6 times higher than that of a wild type.

To provide a tomato plant with improved insect resistance, particularly resistance to whiteflies or mites, the tomato plant including an SlAT2 gene that encodes an acetyl-CoA-dependent acyltransferase enzyme and an AP2e gene that encodes an APETALA2 ethylene-responsive transcription factor.SOLUTION: The present invention relates to methods for preparing a tomato plant having improved insect resistance, and to use of an SlAT2 gene in combination with an AP2e gene for providing an insect-resistant tomato plant.SELECTED DRAWING: None

The disclosure provides, in various embodiments, polynucleotides encoding a fusion protein, wherein the polynucleotides comprise: (a) a protein coding sequence encoding a non-Hedgehog therapeutic protein, and (b) at least one of the following: (i) a sequence encoding a polypeptide sufficient for palmitoylation by a Hedgehog acyltransferase, wherein the polypeptide is N-terminal to the non-Hedgehog therapeutic protein, (ii) a sequence encoding a Hedgehog auto-processing domain having sterol modification activity, wherein the domain is C-terminal to the non-Hedgehog therapeutic protein, and (iii) a sequence encoding a polypeptide sufficient for palmitoylation by a membrane-bound O-acyltransferase enzyme. The disclosure also provides, in various embodiments, vectors, cells, and kits comprising the polynucleotides, and methods of using the polynucleotides, vectors, cells, and / or kits.

The invention discloses application of a membrane-bound O-acyltransferase structural domain 7 (Mboat7) in preparation of a medicine for treating myocardial hypertrophy, and belongs to the technical field of biology. Research results show that in a mouse cardiac hypertrophy model, compared with a control group mouse, heart weight / body weight, lung weight / body weight, cardiac muscle cell cross sectional area and fibrosis of a cardiac muscle cell specific Mboat7 gene overexpressed mouse are all remarkably reduced, and the cardiac systolic function is remarkably improved; the overexpressed Mboat7 gene can relieve isolated cell myocardial hypertrophy induced by angiotensin II. Particularly, overexpression of the Mboat7 gene can improve damage of mitochondria in myocardial tissue of a cardiac hypertrophy mouse. The results show that the Mboat7 gene overexpression relieves the disease progress of the pathological cardiac hypertrophy, and the Mboat7 or the expression promoter thereof can be used for preparing the medicine for preventing, relieving and / or treating the pathological cardiac hypertrophy.

Provided is an RNAi agent for inhibiting DGAT2 gene expression in cells, and a pharmaceutical composition thereof. Also provided is a therapeutic use of the RNAi agent.